Search Results for: Understanding+Chronic+

IFFGD Vice President, William Norton, submitted the following written comments to Noridian Administrative Services in response to the decision by Noridian to deny Medicare coverage for the Solesta procedure for the treatment of fecal incontinence in adults who fail conservative therapy. On behalf of the International Foundation for Functional Gastrointestinal Disorders (IFFGD) I am writing […]

The following written comments were submitted to the Dockets Management Staff (HFA-305) Food and Drug Administration by IFFGD President, Ceciel T. Rooker, in response to Docket No. FDA-2019-D-4247 on December 30, 2019.     Thank you for your leadership at the Center for Drug Evaluation and Research in the Food and Drug Administration (FDA). The International Foundation for […]

IFFGD Vice-President, William Norton, submitted the following written public testimony to the FDA in connection with a January 11, 2012 meeting of the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee to consider the premarket approval of the LINX Reflux Management System for the treatment of gastroesophageal reflux disease (GERD): On behalf […]

IFFGD President, Ceciel Rooker, submitted the following written statement to the House and Senate Committee on Appropriations, Subcommittee on Labor, Health and Human Services, Education, and Related Agencies regarding Fiscal Year (FY) 2020 appropriations for medical research and public health programs. April 9, 2019       STATEMENT OF CECIEL T. ROOKER PRESIDENT INTERNATIONAL FOUNDATION FOR […]